CAL
SIOX

Capital Advisors Ltd’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Capital Advisors Ltd’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,305
Closed -$1K – 1652
2022
Q4 		$1K Sell
1,305
-687
-34% -$223 ﹤0.01% 1160
2022
Q3 		$1K Buy
1,992
+687
+53% +$235 ﹤0.01% 1188
2022
Q2 		$0 Buy
+1,305
New +$540 ﹤0.01% 1444

Other funds holding SIOX

JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Capital Advisors Ltd's SIOX Position: Q1 2023 in Review

Capital Advisors Ltd sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 1,305 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in SIOX in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q4 2022. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

  • Capital Advisors Ltd reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 1,305 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $1K.
  • Capital Advisors Ltd first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Capital Advisors Ltd's Sio Gene Therapies Inc. Common Stock position peaked at $1K in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Capital Advisors Ltd's 13F filing for Q1 2023, filed 3 May 2023.